What ChondroFiller is and which hip patients it suits

ChondroFiller is not a standard hip injection. Unlike corticosteroids, which reduce inflammation, or hyaluronic acid, which lubricates the joint, ChondroFiller is a CE-marked Class III injectable collagen scaffold — a structured material that gels inside the joint and supports the body's own repair processes through a process called acellular matrix-induced chondrogenesis.

Manufactured by Meidrix Biomedicals in Germany, the product is supplied in a dual-chamber syringe containing acid-extracted Type I collagen. It is entirely cell-free: rather than delivering donor or patient cells, the porous scaffold recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone after it has been placed.

The clinical indication is specific. ChondroFiller is designed for focal Grade III or IV articular cartilage defects — a contained area of near- or full-thickness cartilage loss on the femoral head or acetabulum, typically between 2 cm² and 6 cm², with a preserved joint space on weight-bearing X-ray. It is not intended for diffuse, end-stage osteoarthritis, where the joint space has already collapsed.

The procedure itself is an outpatient appointment: no operating theatre, no general anaesthetic, no incision. Lincolnshire Hip offers this pathway for suitable patients across Lincolnshire and the wider non-London catchment and accepts patients without a GP referral.

Before the appointment: what assessment and preparation involve

Once a treating clinician has reviewed a patient's imaging and confirmed they are a suitable candidate — typically on the basis of an MRI scan that characterises the cartilage defect in detail — preparation for the appointment itself is straightforward. Because ChondroFiller is delivered as an outpatient clinic injection rather than a theatre procedure, the pre-admission demands of surgery simply do not apply: there is no requirement to fast overnight, no pre-operative anaesthetic assessment, and no hospital admission.

The most important practical step beforehand is a conversation about current medications. Anticoagulants and certain anti-inflammatory drugs may need to be paused in the days before an intra-articular injection; the treating clinician will advise on timing based on the specific medication.

Antibiotic cover is included as standard within the procedure package to reduce the small risk of infection associated with any intra-articular injection. This is given intravenously at the appointment — a brief, routine step rather than a cause for concern.

Patients can plan to travel home the same day. Standard post-injection driving precautions apply: it is sensible to arrange for someone else to drive immediately afterwards, particularly if a local anaesthetic has been used around the hip, and to confirm this with the clinical team in advance.

Step by step: from skin anaesthetic to gel delivery

The appointment follows a predictable sequence, and understanding each stage in advance tends to reduce anxiety on the day.

The first step is applying a local anaesthetic to the skin and the soft tissues surrounding the hip. This numbs the area before the needle is introduced, so most patients experience little more than mild pressure during the procedure itself.

With the patient positioned and the anaesthetic given time to work, the clinician applies an ultrasound probe to the skin. The hip joint sits deeper than many patients expect — the femoral head typically lies six to eight centimetres below the surface — and the femoral artery, vein, and nerve run in close proximity to the injection path. Real-time ultrasound imaging allows the clinician to visualise these structures as the needle is advanced, steering around them with precision. Because ultrasound uses sound waves rather than ionising radiation, it can be used freely in an outpatient clinic setting without the restrictions that apply to fluoroscopy.

Once the needle tip is confirmed at the target site within the hip joint, the ChondroFiller syringe is engaged. The product's two components are kept separate until this point and mix only as they pass through the needle on delivery. This controlled mixing triggers the in-situ gelling reaction.

The mixed gel settles over the worn cartilage surface and sets within approximately three to five minutes, forming a stable, self-adherent collagen matrix without any requirement to prepare the underlying bone bed. From needle insertion to completion, the entire procedure takes roughly ten minutes.

There is no incision to close and no wound to dress. The appointment ends, and the patient is free to leave the clinic on the same day.

How the scaffold works inside the hip joint

From the moment the gel sets against the worn cartilage surface, it is doing two distinct jobs simultaneously: a structural one and a biological one.

Structurally, the hardened collagen matrix provides immediate mechanical coverage over the focal defect — a cushioning layer present from day one, sitting between the damaged surface and the opposing joint face with every step taken during the protected recovery period.

The biological process unfolds more gradually. The scaffold's porous architecture draws the patient's own progenitor cells in from the surrounding tissue over the following weeks, and those cells may differentiate and begin synthesising cartilage-like material within the matrix — a process termed acellular matrix-induced chondrogenesis. Most patients begin to notice clinical improvement between six and twelve weeks after injection, with further gains building over the subsequent six to twelve months as newly formed tissue consolidates within the scaffold.

The scaffold itself does not remain permanently. Over approximately one to two years it is gradually resorbed by the body, leaving behind whatever tissue has formed within it. It functions as a temporary architectural framework: present long enough to support repair, then cleared away.

This structural intent is what sets the approach apart from symptom-management injections. Hyaluronic acid eases lubrication; corticosteroid addresses acute inflammation. Neither provides a three-dimensional scaffold for tissue formation. The goals are genuinely different, and patients weighing injection options benefit from understanding which end of that spectrum each treatment occupies.

Hip-specific outcome data are more limited than the established knee evidence base. A prospective cohort of 26 hip patients showed 17 of 21 achieving good or excellent results at three to five years of follow-up; a 2025 peer-reviewed case report documented complete pain relief after ChondroFiller application to a 15 mm × 5 mm focal femoral head defect. The evidence base is growing, and hip-specific outcome expectations should be held at that level of realism.

Leaving the clinic: immediate aftercare and weight-bearing

Discharge from the clinic follows directly after the procedure — no overnight stay is needed, and most patients walk out unaided. There is no incision to manage and no general anaesthetic to recover from, so the immediate hours afterwards are straightforward for most people.

That said, the weeks that follow carry one clear practical instruction: avoid full weight-bearing on the affected hip for approximately six weeks. The rationale is grounded in biomechanics — in-vitro testing has shown that the ChondroFiller scaffold has initial instability under full cyclic loading before it has had time to integrate with the surrounding tissue. A period of partial loading gives the collagen matrix the conditions it needs to stabilise and anchor in place, which is why this restriction is built into the standard aftercare protocol.

Low-impact movement during those six weeks is actively encouraged to maintain circulation and prevent stiffness. After the initial protected period, a graduated return begins — swimming and cycling are the typical starting points, allowing load to increase progressively as the scaffold continues to consolidate. Higher-impact activities, including running, are reintroduced later and at a pace guided by clinical assessment.

A six-week follow-up is included as a standard part of the care pathway at MSK Doctors group clinics, giving the treating clinician the opportunity to review progress, check integration, and advise on the next stage of return to activity.

When improvement typically arrives

The clinical benefit from a ChondroFiller hip injection does not arrive immediately — and knowing that in advance is useful preparation.

Most patients report the first meaningful change in hip pain and function between six and twelve weeks post-injection. The scaffold needs several weeks to integrate before recruited progenitor cells begin synthesising cartilage-like tissue in any quantity; early symptomatic relief in that window owes as much to the collagen matrix's mechanical cushioning as to completed tissue formation. Continued gains accumulate over six to twelve months as new tissue matures within the scaffold.

Hip-specific outcome data support a measured level of optimism. Published cohort data suggest an average improvement of approximately 30 points on the modified Harris Hip Score — a validated measure of hip pain and function used across hip cartilage studies. The evidence gap is worth one honest sentence: large RCT data for ChondroFiller come predominantly from knee studies; hip evidence rests on prospective cohort series and peer-reviewed case reports rather than RCT-level confirmation, and should be understood on that basis.

The six-week follow-up included in the care pathway offers a structured review point before consolidation is complete, allowing the treating clinician to assess early integration and refine activity guidance before the tissue-maturation phase is under way.

ChondroFiller is a private self-funded treatment in the UK and is not FDA-cleared. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment. For suitable candidates — a focal cartilage defect confirmed on MRI, preserved joint space, and conservative management already attempted — the published evidence suggests that the most demanding part of the process is the patience required in those first twelve weeks, rather than the procedure itself.

1. [1] Hip Arthroscopy and Chondrofiller Application in Isolated Osteochondral Defect of the Femoral Head. (2025). https://doi.org/10.13107/jocr.2025.v15.i10.6176 https://doi.org/10.13107/jocr.2025.v15.i10.6176